CN122182592A - 药物组合物和使用其治疗癌症的方法 - Google Patents

药物组合物和使用其治疗癌症的方法

Info

Publication number
CN122182592A
CN122182592A CN202610493906.4A CN202610493906A CN122182592A CN 122182592 A CN122182592 A CN 122182592A CN 202610493906 A CN202610493906 A CN 202610493906A CN 122182592 A CN122182592 A CN 122182592A
Authority
CN
China
Prior art keywords
effective amount
decitabine
subject
dosage form
cidyuridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202610493906.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·欧加内斯安
金姆-希恩·达奥
H·科尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dapeng Pharmaceutical Co ltd
Original Assignee
Dapeng Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dapeng Pharmaceutical Co ltd filed Critical Dapeng Pharmaceutical Co ltd
Publication of CN122182592A publication Critical patent/CN122182592A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202610493906.4A 2020-10-29 2021-10-27 药物组合物和使用其治疗癌症的方法 Pending CN122182592A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063107010P 2020-10-29 2020-10-29
US63/107,010 2020-10-29
PCT/US2021/056809 WO2022093930A1 (en) 2020-10-29 2021-10-27 Pharmaceutical compositions and methods of using the same for treating cancer
CN202180052939.0A CN116018145A (zh) 2020-10-29 2021-10-27 药物组合物和使用其治疗癌症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180052939.0A Division CN116018145A (zh) 2020-10-29 2021-10-27 药物组合物和使用其治疗癌症的方法

Publications (1)

Publication Number Publication Date
CN122182592A true CN122182592A (zh) 2026-06-12

Family

ID=81384423

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202610493906.4A Pending CN122182592A (zh) 2020-10-29 2021-10-27 药物组合物和使用其治疗癌症的方法
CN202180052939.0A Pending CN116018145A (zh) 2020-10-29 2021-10-27 药物组合物和使用其治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180052939.0A Pending CN116018145A (zh) 2020-10-29 2021-10-27 药物组合物和使用其治疗癌症的方法

Country Status (10)

Country Link
US (1) US12697347B2 (cg-RX-API-DMAC7.html)
EP (1) EP4237094A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023548303A (cg-RX-API-DMAC7.html)
KR (1) KR20230097034A (cg-RX-API-DMAC7.html)
CN (2) CN122182592A (cg-RX-API-DMAC7.html)
AU (1) AU2021369508B2 (cg-RX-API-DMAC7.html)
CA (1) CA3188316A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023003305A (cg-RX-API-DMAC7.html)
TW (1) TW202227096A (cg-RX-API-DMAC7.html)
WO (1) WO2022093930A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US9834576B2 (en) 2013-10-29 2017-12-05 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
SG11202108523UA (en) * 2019-03-25 2021-09-29 Otsuka Pharma Co Ltd Antitumor composition
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
WO2021113688A1 (en) 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
LT4069254T (lt) 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
JP2024521824A (ja) 2021-05-27 2024-06-04 ヴァンダービルト ユニヴァーシティ マクロライド化合物
MX2024003537A (es) 2021-09-21 2024-05-03 Otsuka Pharma Co Ltd Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina.

Also Published As

Publication number Publication date
JP2023548303A (ja) 2023-11-16
CN116018145A (zh) 2023-04-25
TW202227096A (zh) 2022-07-16
KR20230097034A (ko) 2023-06-30
CA3188316A1 (en) 2022-05-05
AU2021369508B2 (en) 2026-07-09
US20230405037A1 (en) 2023-12-21
US12697347B2 (en) 2026-08-04
WO2022093930A1 (en) 2022-05-05
JP2026083415A (ja) 2026-05-19
MX2023003305A (es) 2023-04-13
AU2021369508A1 (en) 2023-03-02
EP4237094A4 (en) 2024-07-10
EP4237094A1 (en) 2023-09-06

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination